Mainz Biomed (NASDAQ:MYNZ – Free Report) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Mainz Biomed in a note issued to investors on Monday, November 25th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.07) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Mainz Biomed’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Mainz Biomed’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.23) EPS.
Mainz Biomed Stock Up 8.8 %
Shares of Mainz Biomed stock opened at $0.23 on Tuesday. Mainz Biomed has a 12 month low of $0.19 and a 12 month high of $1.79. The business has a fifty day simple moving average of $0.26 and a 200-day simple moving average of $0.39.
Mainz Biomed Company Profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Further Reading
- Five stocks we like better than Mainz Biomed
- How Investors Can Find the Best Cheap Dividend Stocks
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Investing In Automotive Stocks
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
